Efficacy and Safety of Asparaginase-Containing Treatment Regimens in ALL/LBL and Beyond – An Interactive Review for Oncology Nurses and Nurse Practitioners

August 17, 2023

This CEC Oncology ONS Chapters Series is targeted to oncology nurses and advanced nurse practitioners serving as part of an interprofessional healthcare team providing care for pediatric and adult patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). To introduce this session, learners will first understand the rationale for using asparaginase, both in ALL/LBL and in other disease states. Following this, a discussion of clinical trial data supporting asparaginase-containing regimens along with relevant product-distinguishing information will highlight must-know information for involved oncology nurses. In conclusion, the focus will shift toward toxicities associated with asparaginase use and the differences among infusion reactions and hypersensitivity reactions that can make routine use of and adherence to these therapies challenging in real-world settings. An interactive case-based approach will then serve to solidify these important concepts and integrate newly acquired practical information.

Target Audience

Oncology nurses and nurse practitioners attending local ONS Chapter Meetings across the U.S.

Learning Objectives

  • Examine the rationale for using asparaginase in the treatment of pediatric and adult/young adult acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) as well as other disease states.
  • Appraise key clinical trial data of different asparaginase-containing regimens in ALL/LBL and apply that knowledge to selection of optimal asparaginase-containing treatment, based on patient-specific factors as well as the latest data.
  • Identify the different asparaginase products available, and distinguish them based upon dose, route, formulation, proper monitoring, PK profiles, and unique safety concerns.
  • Recognize asparaginase related toxicities that lead to poorer patient prognosis, identify the difference between asparaginase infusion reactions and clinical/subclinical hypersensitivity, develop monitoring/interpretation strategies for serum asparaginase levels to optimize treatment, and understand silent inactivation.
  • Using a case-based approach, formulate clinical strategies for asparaginase-containing regimens, focusing on efficacy and safety of different formulations, and practice approaches to monitor asparaginase levels while also preventing and mitigating asparaginase-related toxicities.

Presented by Creative Educational Concepts, LLC.

Supported through an independent educational grant from Jazz Pharmaceuticals.

Additional Information

AttachmentSize
PDF icon Handout and References5.51 MB
PDF icon General Information837.32 KB
PDF icon Topline Takeaway389.33 KB
Course summary
Available credit: 
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
05/22/2023
Course expires: 
09/17/2023
Event starts: 
08/17/2023 - 6:00pm EDT
Event ends: 
08/17/2023 - 7:00pm EDT

  5 minutes      Welcome and Introductions/Pre-test
10 minutes      The Role of Asparaginase: Mechanism in ALL/LBL and Other Disease States 
20 minutes      Bolstering Confidence in the Use of Asparaginase-Containing Treatment Regimens: A Data-Driven Discussion for Optimal Management 
15 minutes      Zeroing in On Safety and Defining the Difference: Infusion Reactions, Hypersensitivity, and Monitoring in Clinical Practice   
10 minutes      Conversations with the Expert/Audience Q&A
 

Gwinnett ONS
Live Virtual Event
United States

Sandra Kurtin, PhD, ANP-C, AOCN
Nurse Practitioner
Assistant Professor of Clinical Medicine
Assistant Professor of Nursing
The University of Arizona Cancer Center
Tucson, AZ

 


It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planner/Faculty:
Sandra Kurtin, PhD, ANP-C, AOCN–has disclosed that she is an advisor or consultant to Abbvie, Agios, Amgen, Astra Zeneca, Bristol Myers Squibb, lncyte, and Takeda.

Peer Reviewer:
Stacy Muddiman, BSN, RN, OCN–has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff:
Katherine Lee, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Nursing (ANCC)
This activity is designated for 1.0 contact hour.

Upon completion of a CNE request form, statements of credit for nurses will be issued within 30 business days.

ONCC/ILNA Certification Information:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CPHON, BMTCN, OCN, AOCNP, and CBCN nurses may apply 1.0 point in Care of the Pediatric Hematology and Oncology Patient, Cellular Collection, Preparative Regimens and Infusion, Foundations of Transplant, Oncologic Emergencies, Oncology Nursing Practice, Pediatric Hematology and Oncology Nursing Practice, Professional Practice/Performance, Symptom Management, Palliative Care, Supportive Care, Transplant Process and Infusion, and Treatment categories. 

Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Available Credit

  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.